Hinova Pharmaceuticals (SH:688302)2025-02-27 09:45Revenue and Profit - Total revenue for 2024 was RMB 366,800, with no revenue in the same period last year[4] - Net profit attributable to the parent company was a loss of RMB 198,049.7, an improvement of RMB 96,108.8 compared to the previous year[6] - Basic earnings per share were -RMB 2.00, compared to -RMB 2.97 in the previous year[4] Expenses - Research and development expenses amounted to RMB 172,285.7, a decrease of 30.6% from RMB 248,268.0 in the previous year[6] - The company has increased its sales expenses in preparation for the commercialization of HC-1119[6] Assets and Equity - Total assets at the end of the reporting period were RMB 1,361,604.8, a decrease of 8.71% year-on-year[6] - Equity attributable to the parent company was RMB 1,192,663.1, down 12.76% from the beginning of the period[4] Commercialization and R&D Focus - The company has not yet obtained commercial sales approval for any drugs, resulting in no drug sales revenue[7] - The company is focusing on optimizing its R&D pipeline and accelerating key project advancements[6] Financial Reporting - The financial data presented is preliminary and unaudited, with final results to be disclosed in the annual report[8]